Patent · US Active

Neutralizing human anti-IGFR antibody

US7847068B2 · kind B2 · utility

2Cited by

36References

99Claims

0Family size

Assignee

SCHERING CORPORATION · US

Inventors

Yan Wang · San Diego, US
Robert Greenberg · Sparta, US
Leonard G. Presta · San Francisco, US
Jonathan A. Pachter · Setauket, US
Judith Hailey · Edison, US
Peter Brams · Sacramento, US
Denise Williams · San Jose, US
Mohan Srinivasan · Cupertino, US
Diane Feingersh · Union City, US

Key dates

Filing date	Nov 13, 2006
Grant date	Dec 7, 2010
Priority date	—
Expiry date	Nov 9, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.